NCT07186478View on ClinicalTrials.gov

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

NAActive, not recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

October 20, 2025

Study Completion Date

October 20, 2025

Conditions
Pulmonary TuberculosisHypoalbuminemia
Interventions
DRUG

Investigational Drug

IFALMIN® is a standardized herbal preparation derived from Channa micropeltes (ikan toman), containing natural albumin. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.

DRUG

Placebo

Placebo capsule containing inert ingredients (such as starch/lactose), identical in appearance, size, and color to IFALMIN® capsule. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.

Trial Locations (1)

90245

RSUD Wahidin Sudirohusodo, Makassar

All Listed Sponsors
collaborator

RSUP Dr. Wahidin Sudirohusodo

OTHER

lead

Hasanuddin University

OTHER

NCT07186478 - I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter